Ex vivo expansion of natural killer cells with high cytotoxicity by K562 cells modified to co-express major histocompatibility complex class I chain-related protein A, 4-1BB ligand, and interleukin-15

Tissue Antigens

Volumn 76, Issue 6, 2010, Pages 467-475

  Gong, W ^a   Xiao, W ^a   Hu, M ^a   Weng, X ^a   Qian, L ^a   Pan, X ^a   Ji, M ^a  

^a YANGZHOU UNIVERSITY   (China)

Author keywords

4 1BBL; Expansion; IL 15; MICA; Natural killer

Indexed keywords

CD137 ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 15; PROTEIN A;

ARTICLE; CELL ACTIVATION; CELL CULTURE; CELL EXPANSION; CELL SURVIVAL; CONTROLLED STUDY; CYTOTOXICITY; EX VIVO STUDY; HUMAN; HUMAN CELL; MAJOR HISTOCOMPATIBILITY COMPLEX; NATURAL KILLER CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION;

4-1BB LIGAND; COCULTURE TECHNIQUES; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; IMMUNOTHERAPY; INTERFERON-GAMMA; INTERLEUKIN-15; K562 CELLS; KILLER CELLS, NATURAL; LYMPHOCYTE ACTIVATION;

EID: 78149373129     PISSN: 00012815     EISSN: 13990039     Source Type: Journal    
DOI: 10.1111/j.1399-0039.2010.01535.x     Document Type: Article

References (26)

1. Vivier E, Tomasello E, Baratin M, Walzer T, Ugolini S. Functions of natural killer cells. Nat Immunol 2008: 9: 503-10.
2. Nausch N, Cerwenka A. NKG2D ligands in tumor immunity. Oncogene 2008: 27: 5944-58.
3. Velardi A, Ruggeri L, Mancusi A, Aversa F, Christiansen FT. Natural killer cell allorecognition of missing self in allogeneic hematopoietic transplantation: a tool for immunotherapy of leukemia. Curr Opin Immunol 2009: 21: 525-30.
4. Lanier LL. NK cell recognition. Annu Rev Immunol 2005: 23: 225-74.
5. Bahram S, Bresnahan M, Geraghty DE, Spies T. A second lineage of mammalian major histocompatibility complex class I genes. Proc Natl Acad Sci U S A 1994: 91: 6259-63.
6. Cerwenka A, Baron JL, Lanier LL. Ectopic expression of retinoic acid early inducible-1 gene (RAE-1) permits natural killer cell-mediated rejection of a MHC class I-bearing tumor in vivo. Proc Natl Acad Sci U S A 2001: 98: 11521-26.
7. Von Strandmann EP, Hansen HP, Reiners KS et al. A novel bispecific protein (ULBP2-BB4) targeting the NKG2D receptor on natural killer (NK) cells and CD138 activates NK cells and has potent antitumor activity against human multiple myeloma in vitro and in vivo. Blood 2006: 107: 1955-62.
8. Latouche JB, Sadelain M. Induction of human cytotoxic T lymphocytes by artificial antigen-presenting cells. Nat Biotechnol 2000: 18: 405-9.
9. + T cells ex vivo. Cell Mol Immunol 2008: 5: 47-53.
10. Cheuk ATC, Mufti GJ, Guinn B. Role of 4-1BB: 4-1BB ligand in cancer immunotherapy. Cancer Gene Ther 2004: 11: 215-26.
11. Budagian V, Bulanova E, Paus R, Bulfone-Paus S. IL-15/IL-15 receptor biology: A guided tour through an expanding universe. Cytokine Growth Factor Rev 2006: 17: 259-80.
12. Fujisaki H, Kakuda H, Shimasaki N et al. Expansion of highly cytotoxic human natural killer cells for cancer cell therapy. Cancer Res 2009: 69: 4010-17.
13. Imai C, Iwamoto S, Campana D. Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells. Blood 2005: 106: 376-83.
14. Roberts AI, Lee L, Schwarz E et al. NKG2D receptors induced by IL-15 costimulate CD28-negative effector CTL in the tissue microenvironment. J Immunol 2001: 167: 5527-30.
15. Colucci F. Unexpected partnership between IL-15 and DAP10. Nat Immunol 2007: 8: 1289-91.
16. Horng T, Bezbradica JS, Medzhitov R. NKG2D signaling is coupled to the interleukin 15 receptor signaling pathway. Nat Immunol 2007: 8: 1345-52.
17. Sutherland CL, Rabinovich B, Jan Chalupny N et al. ULBPs, human ligands of the NKG2D receptor, stimulate tumor immunity with enhancement by IL-15. Blood 2006: 108: 1313-19.
18. Alter G, Malenfant JM, Altfeld M. CD107a as a functional marker for the identification of natural killer cell activity. J Immunol Methods 2004: 294: 15-22.
19. Kantakamalakul W, Jaroenpool J, Pattanapanyasat K. A novel enhanced green fluorescent protein (EGFP)-K562 flow cytometric method for measuring natural killer (NK) cell cytotoxic activity. J Immunol Methods 2003: 272: 189-97.
20. + NK cells interacting with monocyte-derived DC or EBV cell lines: regulation by KIR/HLA-class I interaction. Blood 2009: 114: 4108-16.
21. Wendel M, Galani IE, Suri-Payer E, Cerwenka A. Natural killer cell accumulation in tumors is dependent on IFN-gamma and CXCR3 ligands. Cancer Res 2008: 68: 8437-45.
22. Andre P, Castriconi R, Espeli M et al. Comparative analysis of human NK cell activation induced by NKG2D and natural cytotoxicity receptors. Eur J Immunol 2004: 34: 961-71.
23. Wiemann K, Mittrucker HW, Feger U et al. Systemic NKG2D down-regulation impairs NK and CD8 T cell responses in vivo. J Immunol 2005: 175: 720-29.
24. Oppenheim DE, Roberts SJ, Clarke SL et al. Sustained localized expression of ligand for the activating NKG2D receptor impairs natural cytotoxicity in vivo and reduces tumor immunosurveillance. Nat Immunol 2005: 6: 928-37.
25. Alici E, Sutlu T, Björkstrand B et al. Autologous antitumor activity by NK cells expanded from myeloma patients using GMP-compliant components. Blood 2008: 111: 3155-62.
26. Zhang C, Zhang J, Niu J, Zhang J, Tian Z. Interleukin-15 improves cytotoxicity of natural killer cells via up-regulating NKG2D and cytotoxic effector molecule expression as well as STAT1 and ERK1/2 phosphorylation. Cytokine 2008: 42: 128-36.